In the past week, ACAD stock has gone up by 2.09%, with a monthly decline of -15.94% and a quarterly surge of 5.86%. The volatility ratio for the week is 2.37%, and the volatility levels for the last 30 days are 3.76% for Acadia Pharmaceuticals Inc The simple moving average for the past 20 days is -3.58% for ACAD’s stock, with a -21.72% simple moving average for the past 200 days.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
The price-to-earnings ratio for Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is above average at 90.14x, Company’s 36-month beta value is 0.40.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ACAD is 164.61M, and currently, short sellers hold a 6.99% ratio of that floaft. The average trading volume of ACAD on August 27, 2024 was 1.81M shares.
ACAD) stock’s latest price update
Acadia Pharmaceuticals Inc (NASDAQ: ACAD)’s stock price has increased by 0.94 compared to its previous closing price of 15.94. However, the company has seen a 2.09% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-26 that Shares of Acadia trended lower this year due to Daybue’s poor quarterly sales performance, and also due to Nuplazid’s failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Morgan Stanley repeating the rating for ACAD by listing it as a “Equal-Weight.” The predicted price for ACAD in the upcoming period, according to Morgan Stanley is $20 based on the research report published on August 07, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $31. The rating they have provided for ACAD stocks is “Outperform” according to the report published on June 27th, 2024.
Needham gave a rating of “Buy” to ACAD, setting the target price at $32 in the report published on March 12th of the current year.
ACAD Trading at -3.76% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.63% of loss for the given period.
Volatility was left at 3.76%, however, over the last 30 days, the volatility rate increased by 2.37%, as shares sank -14.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.63% upper at present.
During the last 5 trading sessions, ACAD rose by +2.09%, which changed the moving average for the period of 200-days by -31.53% in comparison to the 20-day moving average, which settled at $16.56. In addition, Acadia Pharmaceuticals Inc saw -48.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Schneyer Mark C., who sale 9,733 shares at the price of $15.28 back on Aug 19 ’24. After this action, Schneyer Mark C. now owns 43,735 shares of Acadia Pharmaceuticals Inc, valued at $148,720 using the latest closing price.
Teehan Brendan, the EVP, COO, HEAD OF COMMERCIAL of Acadia Pharmaceuticals Inc, sale 9,534 shares at $15.28 during a trade that took place back on Aug 19 ’24, which means that Teehan Brendan is holding 52,177 shares at $145,680 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.03. The total capital return value is set at 0.04. Equity return is now at value 6.70, with 3.93 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 1.4.
Currently, EBITDA for the company is -67.83 million with net debt to EBITDA at -3.67. When we switch over and look at the enterprise to sales, we see a ratio of 2.86. The receivables turnover for the company is 8.07for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
In a nutshell, Acadia Pharmaceuticals Inc (ACAD) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
